Ayisha joined Scrip in 2021 after working as an investigative reporter at GlobalData's pharmaceutical news platform, BioPharm Insight, where she covered the beats of hematology, oncology and rare diseases. She holds an MA in Philosophy from University College London and an NCTJ diploma in multimedia journalism. Ayisha is interested in psychiatric disorders and drug development focused on the microbiome.
Latest From Ayisha Sharma
Gilead Waives Acquisition Option As Pionyr Explores Other Strategies
Gilead has waived its option to acquire Pionyr, allowing the US biotech to explore other partnerships and financing opportunities as it advances a promising pipeline of macrophage-targeting antibodies.
Executives On The Move: Roche, Vanda Pharmaceuticals And More
Recent executive changes in the industry include C-suite changes at Roche and Quince Therapeutics. Meanwhile, new directors were appointed at Vanda Pharmaceuticals and MAIA Biotechnology.
Incyte’s US Approval For PD-1 Inhibitor Zynyz In MCC Draws Muted Response
The US firm’s Zynyz has won accelerated approval for the treatment of first-line Merkel cell carcinoma, bouncing back from a prior regulatory setback, but its third-to-market status leaves it with the crumbs under the table in this orphan indication.
Altimmune’s Pemvidutide Garners Mixed Reviews Following Phase II Obesity Data
The US firm’s GLP-1/glucagon receptor agonist improved weight loss in a Phase II interim analysis, but concerns about drug safety and discontinuation have left investors cynical, even as analysts remain cautiously upbeat.
Double Blow For Sangamo’s Zinc Finger Approach As Novartis And Biogen Deals Collapse
The US biotech is facing yet another setback on its journey to proof-of-concept for its proprietary gene editing technology as two pharma firms back out of collaborations in the neurological space.
Affibody And UCB Eye Humira’s Weak Spot In Hidradenitis Suppurativa
The rival firms are advancing separate biologic candidates that target IL-17 in a bid to treat the more than 60% of hidradenitis suppurativa patients who remain uncontrolled on AbbVie’s Humira, with recent trial readouts showing promise.